Literature DB >> 33925203

Long-Acting Reversible Contraception: Placement, Continuation, and Removal Rates at an Inner-City Academic Medical Center Clinic.

Aliye Runyan1, Robert A Welch2, Katherine J Kramer3, Sarah Cortez4, LeAnne J Roberts4, Clementina Asamoah4, Sarah Ottum5, Jessica Sanders6, Adib Shafi7, Maurice-Andre Recanati8.   

Abstract

Long-Acting Reversible Contraception (LARCs) has the potential to decrease unintended pregnancies but only if women can easily access a requested method. Retrospective electronic chart review identified women desiring LARC placement over a one-year period ending 31 December 2016. Most of the 311 insertions were for family planning, with 220 new insertions and 60 replacements. Delays occurred in 38% (n = 118) of patients, averaged 5 ± 5 weeks, and 47% received interval contraception. Reasons included absence of qualified provider (n = 44, 37%), pending cultures (n = 31, 26%), and Mirena availability. Teenage LARC use favored Nexplanon whereas older women preferred Mirena (p < 0.01). Of the 11% choosing early LARC removal, a significant number were African Americans (p = 0.040) or teenagers (p = 0.048). Retention time varied by device type; most patients switched to other contraceptives. No patients experienced IUD expulsion. Understanding barriers, attempting to remedy them, and addressing the side effects associated with LARC use is of importance in this inner-city patient population in the United States.

Entities:  

Keywords:  LARC placement delays; inner-city clinic; intrauterine device; long-acting reversible contraception; removal rates

Year:  2021        PMID: 33925203     DOI: 10.3390/jcm10091918

Source DB:  PubMed          Journal:  J Clin Med        ISSN: 2077-0383            Impact factor:   4.241


  44 in total

Review 1.  Barriers to implementation of long-acting reversible contraception: A systematic review.

Authors:  Jessamyn Phillips; Prabjot Sandhu
Journal:  J Am Assoc Nurse Pract       Date:  2018-04       Impact factor: 1.165

2.  Use of Long-Acting Reversible Contraception by Obstetrics and Gynecology Residents: An Examination of Access for All Women.

Authors:  Megan L Evans; Eve Espey; Tony Ogburn; Nikki B Zite
Journal:  Obstet Gynecol       Date:  2018-03       Impact factor: 7.661

3.  Who is using long-acting reversible contraceptive methods? Findings from nine low-fertility countries.

Authors:  Mieke C W Eeckhaut; Megan M Sweeney; Jessica D Gipson
Journal:  Perspect Sex Reprod Health       Date:  2014-07-14

4.  Use of intrauterine devices in nulliparous women.

Authors:  Patricia A Lohr; Richard Lyus; Sarah Prager
Journal:  Contraception       Date:  2016-08-31       Impact factor: 3.375

5.  "I think it depends on the body, with mine it didn't work": explaining young women's contraceptive implant removal.

Authors:  Lesley Hoggart; Victoria Louise Newton; Jane Dickson
Journal:  Contraception       Date:  2013-06-05       Impact factor: 3.375

6.  U.S. women's one-year contraceptive use patterns, 2004.

Authors:  Jennifer J Frost; Susheela Singh; Lawrence B Finer
Journal:  Perspect Sex Reprod Health       Date:  2007-03

7.  "I wish they could hold on a little longer": physicians' experiences with requests for early IUD removal.

Authors:  Jennifer R Amico; Ariana H Bennett; Alison Karasz; Marji Gold
Journal:  Contraception       Date:  2017-05-31       Impact factor: 3.375

8.  Cost effectiveness of contraceptives in the United States.

Authors:  James Trussell; Anjana M Lalla; Quan V Doan; Eileen Reyes; Lionel Pinto; Joseph Gricar
Journal:  Contraception       Date:  2008-09-25       Impact factor: 3.375

9.  Intended and unintended pregnancies worldwide in 2012 and recent trends.

Authors:  Gilda Sedgh; Susheela Singh; Rubina Hussain
Journal:  Stud Fam Plann       Date:  2014-09

10.  Metformin metabolic and vascular effects in normal weight hyperinsulinemic polycystic ovary syndrome patients treated with contraceptive vaginal ring. A pilot study.

Authors:  Cesare Battaglia; Bruno Battaglia; Paolo Casadio; Roberta Rizzo; Paolo G Artini
Journal:  Gynecol Endocrinol       Date:  2020-06-16       Impact factor: 2.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.